Related Experiment Video
Updated: May 3, 2026
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
Published on: March 3, 2015
Comparative drug screening in NUT midline carcinoma
A H Beesley1, A Stirnweiss1, E Ferrari1
1Division of Children's Leukaemia and Cancer Research, Telethon Institute for Child Health Research, University of Western Australia, Perth, Western Australia.
Background:
The NUT midline carcinoma (NMC) is a rare but fatal cancer for which systematic testing of therapy options has never been performed.
Methods:
On the basis of disease biology, we compared the efficacy of the CDK9 inhibitor flavopiridol (FP) with a panel of anticancer agents in NMC cell lines and mouse xenografts.
Results:
In vitro anthracyclines, topoisomerase inhibitors, and microtubule poisons were among the most cytotoxic drug classes for NMC cells, while efficacy of the bromodomain inhibitor JQ1 varied considerably between lines carrying different BRD4 (bromodomain-containing protein 4)-NUT (nuclear protein in testis) translocations. Efficacy of FP was comparable to vincristine and doxorubicin, drugs that have been previously used in NMC patients. All three compounds showed significantly better activity than etoposide and vorinostat, agents that have also been used in NMC patients. Statins and antimetabolites demonstrated intermediate single-agent efficacy. In vivo, vincristine significantly inhibited tumour growth in two different NMC xenografts. Flavopiridol in vivo was significantly effective in one of the two NMC xenograft lines, demonstrating the biological heterogeneity of this disease.
Conclusions:
These results demonstrate that FP may be of benefit to a subset of patients with NMC, and warrant a continued emphasis on microtubule inhibitors, anthracyclines, and topoisomerase inhibitors as effective drug classes in this disease.
Insights
This study evaluated cancer drug efficacy in NUT midline carcinoma (NMC). Flavopiridol showed promise for some patients, alongside established therapies like anthracyclines and microtubule inhibitors.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- NUT midline carcinoma (NMC) is a rare, aggressive cancer with limited treatment options.
- Systematic evaluation of therapeutic strategies for NMC has been lacking.
Purpose of the Study:
- To compare the efficacy of the CDK9 inhibitor flavopiridol (FP) against various anticancer agents in NUT midline carcinoma.
- To identify effective drug classes for NMC based on disease biology.
Main Methods:
- In vitro screening of NMC cell lines and in vivo testing using mouse xenografts.
- Comparative efficacy assessment of flavopiridol, established NMC therapies, and other drug classes.
Main Results:
- Anthracyclines, topoisomerase inhibitors, and microtubule poisons were highly cytotoxic in vitro.
- Flavopiridol demonstrated efficacy comparable to vincristine and doxorubicin, outperforming etoposide and vorinostat.
- In vivo, vincristine was effective in multiple xenografts, while flavopiridol showed efficacy in one, highlighting disease heterogeneity.
Conclusions:
- Flavopiridol may benefit a subset of NMC patients.
- Microtubule inhibitors, anthracyclines, and topoisomerase inhibitors remain crucial therapeutic classes for NMC.
- Further investigation into flavopiridol and other agents is warranted for NMC treatment strategies.
